Compare RTX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | SNY |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.7B | 95.7B |
| IPO Year | 1994 | 2001 |
| Metric | RTX | SNY |
|---|---|---|
| Price | $184.26 | $39.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 10 |
| Target Price | ★ $234.14 | $53.72 |
| AVG Volume (30 Days) | ★ 3.3M | 2.5M |
| Earning Date | 10-20-2026 | 10-30-2026 |
| Dividend Yield | 1.58% | ★ 4.42% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $80,738,000,000.00 | N/A |
| Revenue This Year | $8.54 | $2.00 |
| Revenue Next Year | $7.38 | $6.29 |
| P/E Ratio | $60.07 | ★ $6.14 |
| Revenue Growth | ★ 17.15 | N/A |
| 52 Week Low | $155.64 | $40.40 |
| 52 Week High | $226.88 | $52.68 |
| Indicator | RTX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 22.74 | 27.56 |
| Support Level | $181.57 | N/A |
| Resistance Level | $188.00 | $45.22 |
| Average True Range (ATR) | 3.52 | 0.53 |
| MACD | -0.43 | -0.20 |
| Stochastic Oscillator | 11.79 | 12.96 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.